Medicines Co (MDCO) Earnings Preview For Wednesday's Release
Medicines (NASDAQ:MDCO) is nearing the of release last fiscal quarter's results before the opening bell on February 22, 2012. We can review how Medicines /de has executed for investors recently.
Who They Are:
The Medicines Company, a global pharmaceutical company, provides various medicines to hospitals for advancing the treatment of critical care patients primarily in the United States and Europe. The company was founded in 1996 and is based in Parsippany, New Jersey. Medicines Co shares trade an average of 743,000 shares per day and has a marketcap of $1.1 Billion.
52 Week High: $22.48
52 Week Low: $12.33
Book Value: $8.82
Float Short: 3.85%
What To Expect:
On average, analysts are expecting a drop of $-1.10 in earnings per share compared to last quarter's results of $1.34. Investors will be looking to top $0.24 per share based on the estimated mean earnings.
For the last analyst update, a low of $0.19 and a high of $0.34 per share is what Wall Street is anticipating.
Here is a look at the fiscal year revenue for Medicines. 
Recent Stock and Valuation Performance:
The stock has moved higher in price 10.01% in the last month, and moving in price 25.15% from one year ago.
The stock has done well as compared to the overall market. When comparing to the S&P 500, the year to date difference is 4.08%.
Investors have been rewarded with an increase of year-over-year revenue. Revenue reported was $437.65 million for 2010 vs. $404.24 million for 2009. The bottom line has rising earnings year-over-year of $104.64 million for 2010 vs. $-76.23 million for 2009.The company's earnings before interest and taxes are rising with an EBIT year-over-year of $64.42 million for 2010 vs. $-25.35 million for 2009. Rising revenue along with rising earnings is a very good sign and what we want to see with our companies. Be sure to check the margins in the earnings release to make sure the bottom line is keeping up with the top line.
Here is the last few quarters to get an idea how well they perform compared to estimates 
Reported earnings per share compared to the mean estimate. Differences are rounded.
Paid2Trade uses information believed to be correct, but is not guaranteed and is not independently checked for accuracy You may wish to use this article as a starting point of your own research with your financial planner.
